Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.5% year on year to $391.1 million. On the other hand, the company’s full-year revenue guidance of $1.58 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.59 per share was 3% above analysts’ consensus estimates.
Lantheus (LNTH) Q4 CY2024 Highlights:
Revenue: $391.1 million vs analyst estimates of $377.1 million (10.5% year-on-year growth, 3.7% beat)
Adjusted EPS: $1.59 vs analyst estimates of $1.54 (3% beat)
Management’s revenue guidance for the upcoming financial year 2025 is $1.58 billion at the midpoint, missing analyst estimates by 2.3% and implying 2.8% growth (vs 18.6% in FY2024)
Adjusted EPS guidance for the upcoming financial year 2025 is $7.10 at the midpoint, beating analyst estimates by 1.7%
Operating Margin: 29.1%, down from 38.8% in the same quarter last year
Free Cash Flow Margin: 36.1%, up from 28.3% in the same quarter last year
Market Capitalization: $5.57 billion
“2024 was a groundbreaking year for Lantheus, as our radiodiagnostic, PYLARIFY, reached blockbuster status, and we enhanced our radiopharmaceutical leadership,” said Brian Markison, Chief Executive Officer at Lantheus.
Company Overview
Founded in 1956, Lantheus Holdings (NASDAQ:LNTH) develops and commercializes innovative diagnostic and therapeutic radiopharmaceuticals for healthcare providers, with a focus on oncology, cardiology, and neurology.
https://finance.yahoo.com/news/lantheus-nasdaq-lnth-q4-sales-130659334.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.